The Medical Letter on Drugs and Therapeutics
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The full article is available to subscribers Subscriber Login   

The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa).1 Idarucizumab is the first specific reversal agent to become available for one of the new oral anticoagulants.2

RISK OF BLEEDING WITH DABIGATRAN — As with all anticoagulants, severe, potentially fatal bleeding can occur with dabigatran. Unlike warfarin, routine laboratory monitoring to determine the extent of anticoagulation is not required with dabigatran and no specific agent has been available to reverse its anticoagulant effect in the event of life-threatening bleeding or emergency surgery. Dabigatran is dialyzable, but dialysis may not be feasible in patients with acute bleeding.3

MECHANISM ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Idarucizumab (Praxbind) - An Antidote for Dabigatran
Article code: 1482a
 Electronic, downloadable article - $25